These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 21421727)
1. Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. Heneweer C; Holland JP; Divilov V; Carlin S; Lewis JS J Nucl Med; 2011 Apr; 52(4):625-633. PubMed ID: 21421727 [TBL] [Abstract][Full Text] [Related]
2. Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Ruggiero A; Holland JP; Hudolin T; Shenker L; Koulova A; Bander NH; Lewis JS; Grimm J J Nucl Med; 2011 Oct; 52(10):1608-15. PubMed ID: 21908391 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793 [TBL] [Abstract][Full Text] [Related]
5. Cerenkov luminescence imaging of medical isotopes. Ruggiero A; Holland JP; Lewis JS; Grimm J J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722 [TBL] [Abstract][Full Text] [Related]
6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484 [TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
8. PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. Pérez-Medina C; Tang J; Abdel-Atti D; Hogstad B; Merad M; Fisher EA; Fayad ZA; Lewis JS; Mulder WJ; Reiner T J Nucl Med; 2015 Aug; 56(8):1272-7. PubMed ID: 26112022 [TBL] [Abstract][Full Text] [Related]
9. Probody Therapeutic Design of Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313 [TBL] [Abstract][Full Text] [Related]
10. Development of 68Ga- and 89Zr-Labeled Exendin-4 as Potential Radiotracers for the Imaging of Insulinomas by PET. Bauman A; Valverde IE; Fischer CA; Vomstein S; Mindt TL J Nucl Med; 2015 Oct; 56(10):1569-74. PubMed ID: 26251418 [TBL] [Abstract][Full Text] [Related]
11. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066 [TBL] [Abstract][Full Text] [Related]
13. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376 [TBL] [Abstract][Full Text] [Related]
14. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. Knowles SM; Zettlitz KA; Tavaré R; Rochefort MM; Salazar FB; Stout DB; Yazaki PJ; Reiter RE; Wu AM J Nucl Med; 2014 Mar; 55(3):452-9. PubMed ID: 24504052 [TBL] [Abstract][Full Text] [Related]
15. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091 [TBL] [Abstract][Full Text] [Related]
16. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566 [TBL] [Abstract][Full Text] [Related]
17. Development and characterization of 89Zr-labeled panitumumab for immuno-positron emission tomographic imaging of the epidermal growth factor receptor. Chang AJ; De Silva RA; Lapi SE Mol Imaging; 2013; 12(1):17-27. PubMed ID: 23348788 [TBL] [Abstract][Full Text] [Related]
18. A Hajdu I; Makhlouf A; Solomon VR; Michel D; Al-Dulaymi M; Wasan KM; Fonge H; Badea I Int J Nanomedicine; 2018; 13():7801-7818. PubMed ID: 30538460 [TBL] [Abstract][Full Text] [Related]